Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06507878 · ClinicalTrials.gov registry record
Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
A clinical trial of Thyroid Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 459
- Enrollment target
- 1
- Study location
NCT06507878: Recruiting study of Thyroid Cancer, sponsored by M.D. Anderson Cancer Center.
NCT06507878 is a study of Thyroid Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 459 participants, above the 272-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (69% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06507878, a study of Thyroid Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 459 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.
Primary Outcome
Prospective real-world, large-scale, comprehensive data on these patients who are unable to access traditional clinical trials but are treated with MDA regimens, assigned by stage and BRAF-status.
Conditions Studied
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 459 participants |
| Start Date | 2024-12-05 |
| Est. Completion | 2034-07-01 |
What NCT06507878 shows while recruiting
NCT06507878 is an observational study that tracks outcomes without assigning an intervention. The registered 459 participants enrollment target is mid-sized for trials with a published cap, above the 272-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (69% higher).
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06507878 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06507878 about?
NCT06507878 is a clinical study titled "Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.". The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.
What is the current status of trial NCT06507878?
This trial is currently recruiting. The enrollment target is 459 participants. The study started on 2024-12-05. Estimated completion is 2034-07-01.
What conditions does trial NCT06507878 study?
This clinical trial studies the following conditions: Thyroid Cancer.
Who is sponsoring clinical trial NCT06507878?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06507878 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06507878's enrollment target sits among peer trials
459 5th of 46 higher than 42 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer
RECRUITING
-
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04452825 · 459 participants · NA
A New Psychotherapy Intervention for Older Cancer Patients
- NCT02977780 · 460 participants · Phase 2
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
- NCT03427736 · 460 participants
Anesthetics and Analgesics in Children
- NCT03819933 · 460 participants · NA
Optimizing Family Counseling for Anticipated Extremely Preterm Delivery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI